Optimi Health Welcomes Australia's TGA Framework Update, Expanding Psychedelic Therapy Access

Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage psychedelic pharmaceutical manufacturer, has welcomed final recommendations from Australia’s Therapeutic Goods Administration (TGA) regarding its Authorized Prescriber scheme for psilocybin and MDMA. The updated framework is expected to significantly broaden eligible therapy teams, expand treatment settings beyond hospital environments, and support the scaling of psychedelic-assisted therapy across Australia.

Under the revised guidelines, authorized psychiatrists can prescribe Optimi’s GMP-compliant MDMA for post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistant depression. This expansion is seen as a pivotal step in making these therapies more accessible, particularly in rural and regional areas where workforce capacity has been a limiting factor. The company noted that the changes could accelerate adoption by increasing the number of trained therapists and allowing treatment in a wider range of clinical settings.

Optimi also highlighted that no serious adverse events have been reported under Australia’s regulated commercial psychedelic treatment program since December 2025. This safety record supports continued expansion of what the company describes as the world’s most advanced commercial market for prescribed psilocybin and MDMA therapies. The absence of adverse events is critical for building confidence among regulators, healthcare providers, and patients.

The updated TGA framework is expected to expand reimbursement opportunities across both public and private payers, potentially making treatments more affordable and sustainable. For Optimi, which specializes in the regulated production and international export of MDMA and psilocybin, this development positions the company to capitalize on a growing market. The company’s GMP certification ensures that its products meet stringent quality standards, which is essential for therapeutic use.

This news matters because it represents a tangible step forward in the integration of psychedelic therapies into mainstream mental health care. Australia has emerged as a leader in this space, and the TGA’s updates could serve as a model for other countries considering similar regulatory changes. The implications for Optimi Health are significant: a larger addressable market, increased demand for its products, and potential revenue growth. For patients, the expanded access may offer new treatment options for conditions that have been difficult to treat with conventional therapies.

For more details on the press release, visit https://nnw.fm/yYW7j. Additional information about Optimi Health is available at https://www.optimi.net/.